VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

BioXcel Therapeutics, Inc. (BTAI) Total Return Calculator with Dividends Reinvested

BioXcel Therapeutics, Inc.

Popular:

The total return for BioXcel Therapeutics, Inc. (BTAI) stock is -18.95% over the past 12 months. So far it's down 27.06% this year. The 5-year total return is -99.75%, meaning $10,000 invested in BTAI stock 5 years ago would be worth $25 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in BTAI 1 year ago, it would be worth $8,105 today — you'd have lost $1,895.

With Dividends Reinvested$8,105-18.95%

Price Only (No DRIP)$8,105-18.95%

Period2025-05-07 → 2026-05-07

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in BTAI

1Y$8,105-$1,895 (-19.0%)-19.0% CAGR

3Y$29-$9,971 (-99.7%)-85.7% CAGR

5Y$25-$9,975 (-99.7%)-69.7% CAGR

10Y$70-$9,930 (-99.3%)-39.1% CAGR

15Y$70-$9,930 (-99.3%)-28.1% CAGR

20Y$70-$9,930 (-99.3%)-22.0% CAGR

30Y$70-$9,930 (-99.3%)-15.2% CAGR

BioXcel Therapeutics, Inc. did not pay dividends during this period. Total return = price return.

Loading BTAI total return...

As of 2026-05-07

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-27.06%	—	-27.06%	—	$7,294
1Y	-18.95%	-18.95%	-18.95%	—	$8,105
3Y	-99.71%	-85.67%	-99.71%	—	$29
5Y	-99.75%	-69.74%	-99.75%	—	$25
10Y	-99.30%	-39.09%	-99.30%	—	$70
15Y	-99.30%	-28.15%	-99.30%	—	$70
20Y	-99.30%	-21.96%	-99.30%	—	$70
30Y	-99.30%	-15.23%	-99.30%	—	$70

Risk & Highlights

Best Year+318.62%2019

Worst Year-87.24%2024

Max Drawdown-85.00%2025-08-12 → 2026-04-13

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-1.76%	-1.76%	—	+0.41%	-2.2pp
2025	-74.48%	-74.48%	—	+16.64%	-91.1pp
2024	-87.24%	-87.24%	—	+24.00%	-111.2pp
2023	-86.25%	-86.25%	—	+24.81%	-111.1pp
2022	-5.91%	-5.91%	—	-19.95%	+14.0pp

BTAI underperformed the S&P 500 by 49.33pp over the past year (-18.95% vs +30.37%).

Loading summary...

BTAI Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
BTAIBioXcel Therapeutics, Inc.	$3M	+13.8%	-27.1%	-19.0%	—	-99.7%	-99.7%	-99.3%
ACADACADIA Pharmaceuticals Inc.	$3.9B	+2.2%	-13.7%	+52.4%	—	+4.7%	+7.1%	-22.9%
INVAInnoviva, Inc.	$1.9B	-2.1%	+14.7%	+21.7%	—	+95.2%	+94.4%	+94.9%
AXSMAxsome Therapeutics, Inc.	$11.3B	+30.4%	+23.2%	+98.5%	—	+183.2%	+286.4%	+1886.5%
CORTCorcept Therapeutics Incorporated	$5.5B	+22.5%	+33.6%	-27.5%	—	+114.9%	+141.9%	+929.2%
PTCTPTC Therapeutics, Inc.	$5.3B	-7.3%	-16.0%	+58.2%	—	+16.1%	+60.3%	+733.2%
JAZZJazz Pharmaceuticals plc	$14.2B	+18.9%	+31.1%	+123.7%	—	+63.7%	+30.0%	+53.7%
SUPNSupernus Pharmaceuticals, Inc.	$3.0B	+2.6%	+5.7%	+69.0%	—	+42.1%	+78.0%	+228.4%
PRAXPraxis Precision Medicines, Inc.	$7.5B	+8.7%	+16.4%	+775.0%	—	+1976.5%	-20.8%	-20.1%
IQVIQVIA Holdings Inc.	$30.3B	+4.7%	-20.7%	+16.5%	—	-5.9%	-23.8%	+166.5%
CRLCharles River Laboratories International, Inc.	$9.0B	+7.3%	-10.1%	+32.8%	—	-4.2%	-46.9%	+119.2%

Compare:BTAI vs ACAD BTAI vs INVA BTAI vs AXSM BTAI vs ACAD vs INVA

About BTAI Dividend Returns

BioXcel Therapeutics, Inc. (BTAI) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of BTAI over the past year?

BioXcel Therapeutics, Inc. (BTAI) delivered a return of -18.95% over the past year. Since BTAI does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in BTAI be worth today?

A $10,000 investment in BioXcel Therapeutics, Inc. one year ago would be worth $8,105 today, representing a loss of $1,895.

Q3Does BTAI pay dividends?

BioXcel Therapeutics, Inc. (BTAI) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For BTAI, the total return equals the price-only return.

Q4Did BTAI beat the S&P 500?

No, BioXcel Therapeutics, Inc. (BTAI) underperformed the S&P 500 by 49.33 percentage points over the past year. BTAI delivered a total return of -18.95%, compared to the S&P 500's 30.37%. This means a passive S&P 500 index fund outperformed BTAI by 49.33pp during this period.

Q5What is BTAI's worst drawdown?

BioXcel Therapeutics, Inc. (BTAI) experienced a maximum drawdown of -85.00% over the past year, declining from its peak on 2025-08-12 to its trough on 2026-04-13. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is BTAI's long-term total return over 10, 20, or 30 years?

Here are BioXcel Therapeutics, Inc. (BTAI)'s long-term returns with dividends reinvested. Over 10 years, the total return is -99.3% (-39.1% CAGR) — $10,000 would have grown to $70. Over 20 years: -99.3% total return (-22.0% CAGR) — $10,000 → $70. Over 30 years: -99.3% total return (-15.2% CAGR) — $10,000 → $70. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was BTAI's best and worst year?

BioXcel Therapeutics, Inc.'s best calendar year was 2019 with a total return of 318.6%. Its worst year was 2024 with a total return of -87.2%. This range shows the volatility investors should expect — the difference between the best and worst year is 405.9 percentage points.